Key Drivers
- Strong liquidity
- High gross margins
- Elevated valuation
AIAI Summary
Kiniksa has become a cash-generative, single-product commercial biotech where the investment case now hinges primarily on ARCALYST's ability to sustain high net realizations and meet 2026 revenue guidance—successful execution would justify the premium multiple and fund pipeline bets, while commercial slip-ups or a negative KPL‑387 readout would quickly reverse the upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High gross margins
- •Elevated valuation
KNSA has strong liquidity, high gross margins and cash generation but is weighed by heavy investment, accumulated retained losses and a rich valuation that increases downside risk.
Price Behavior
Key Price Behavior Insights:
- •Mild uptrend
- •Tested resistance
- •Mid‑40s support
Price is mildly bullish over the last month after a 7–8% recovery from the Feb 25 low but remains capped by a clear resistance band near $47.40–$47.80, leaving upside unconfirmed.
~7–8% recovery from
Sentiment & News
Key News Insights:
- •ARCALYST surge
- •EPS miss
- •Pipeline timelines
Kiniksa posted strong ARCALYST revenue and raised 2026 guidance while returning to profitability and boosting cash, but missed Q4 EPS amid ongoing pipeline milestones and investor outreach.
The combination of robust product revenue and improved cash/ guidance supports valuation upside, though near-term sentiment may be tempered by the EPS miss until clinical readouts confirm pipeline momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings